KPV Tablets 500mcg

KPV (Lysine-Proline-Valine Tripeptide)

Primary Function: Anti-inflammatory modulation, gut healing, skin regeneration
Research Use: Inflammatory bowel disease, dermatitis, cytokine suppression, mucosal repair
Molecular Formula: C17H31N5O4
CAS Number: 820876-44-6
Synonyms: α-MSH fragment (11–13), KPV peptide, Lys-Pro-Val

Description:
KPV is a short tripeptide fragment derived from alpha-melanocyte-stimulating hormone (α-MSH), known for its potent anti-inflammatory and immunomodulatory properties. It has been studied extensively for its ability to suppress pro-inflammatory cytokines, reduce local and systemic inflammation, and promote healing in both gastrointestinal and dermatological conditions. KPV exhibits excellent safety and efficacy profiles without triggering melanin production, making it ideal for gut, skin, and systemic inflammation research.

Mechanism of Action:

• Inhibits key pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β
• Interferes with NF-κB signaling pathways to reduce inflammatory gene expression
• Promotes epithelial repair and mucosal healing
• Modulates immune system activity without immunosuppression

Key Research Areas:

• Inflammatory bowel disease (IBD, Crohn’s, colitis)
• Psoriasis, eczema, and dermatitis
• Post-surgical wound healing and scarring
• Mucosal inflammation and GI tract permeability
• Autoimmune and chronic inflammatory conditions

History of Discovery:
KPV was first identified as the C-terminal fragment of alpha-MSH, a naturally occurring anti-inflammatory neuropeptide. Researchers discovered that the tripeptide KPV retains full anti-inflammatory activity without the hormonal effects of full-length α-MSH. This made KPV a targeted therapeutic candidate for topical, oral, and systemic inflammation studies.

Case Studies:

1. IBD Model (2005, Peptides): KPV reduced colon inflammation and histological damage in mice with chemically induced colitis. [Peptides. 2005;26(8):1364–1373.]
2. Topical Application for Skin Inflammation (2009, J Invest Dermatol): KPV alleviated symptoms of contact dermatitis without pigmentation changes. [J Invest Dermatol. 2009;129(4):1066–1073.]
3. Wound Healing Acceleration (2011, Exp Dermatol): KPV promoted faster re-epithelialization and reduced inflammatory markers in cutaneous wound models. [Exp Dermatol. 2011;20(6):468–472.]

Packaging Information:

• Form: Oral Tablets 
• Purity: ≥ 99%
• Storage: Store at -20°C in a dry, dark environment
• For research use only. Not for human or veterinary use.